National Science Foundation

The Kentucky Science and Engineering Foundation (KSEF) is dedicated to fostering innovation by investing in research and development activities. Its primary mission is to stimulate scientific and economic growth within the Commonwealth of Kentucky by building a pipeline of new ideas and technologies. Through its investments, KSEF aims to enhance the state's capacity for innovation and support the development of valuable scientific advancements.

Amphix Bio is engaged in the development of advanced therapeutic materials aimed at regenerative medicine. The company specializes in creating nanofiber materials that replicate the structure and dynamic characteristics of human tissues. By integrating biological signals, these materials instruct cells to activate regenerative processes. Amphix Bio's innovations enable the development of therapies designed to repair a variety of tissues, including bone, cartilage, muscle, cardiovascular tissues, and the brain and spinal cord. The promising results observed in both preclinical and clinical trials highlight the potential of Amphix Bio's approach in transforming therapeutic applications in medicine.

The Wake Forest Institute for Regenerative Medicine (WFIRM) is a leader in translating scientific discovery into clinical therapies. Physicians and scientists at WFIRM were the first in the world to engineer laboratory-grown organs that were successfully implanted into humans. Today, this interdisciplinary team is working to engineer more than 30 different replacement tissues and organs and to develop healing cell therapies-all with the goal to cure, rather than merely treat, disease.

The Wistar Institute is the first independent institution in the United States dedicated to medical research and training, recognized for its significant contributions to biomedical science. Originally established as an anatomical teaching museum, it has transformed into a leading center for basic biomedical research and was designated a National Cancer Institute Cancer Center in 1972. The institute specializes in research areas including immunology, infectious diseases, and vaccine development. Its groundbreaking discoveries have facilitated the creation of vaccines for diseases such as rabies, rubella, and rotavirus, as well as the identification of genes linked to various cancers, including breast, lung, and prostate cancer. Additionally, Wistar has played a crucial role in advancing monoclonal antibodies and other vital research technologies, fostering a collaborative environment aimed at addressing critical health challenges.

Amplified Sciences LLC is a molecular diagnostics company focused on the early detection of debilitating diseases, particularly pancreatic cancer and kidney disease. Utilizing an ultra-sensitive molecular sensing technology licensed from Purdue University, the company’s platform can detect disease markers at the single molecule level, enabling accurate diagnosis from bodily fluids such as urine and saliva. This versatile technology is designed for scalability to point-of-care applications, allowing for effective disease screening with a favorable cost structure. Amplified Sciences has developed a working prototype and has published proof of concept data, positioning itself to meet significant unmet medical needs in diagnostics. Founded in 2016 and based in West Lafayette, Indiana, the company was previously known as Nutrabiotix.

MelliCell is focused on combating chronic diseases through innovative tissue engineering technology, specifically targeting fat cells as a source of therapeutic adipokines. Their platform enables the conversion of human stem cells into large, mature fat cells, which can be used to develop drug therapies aimed at reducing fat mass while preserving lean mass. This unique approach is designed to address conditions such as obesity, diabetes, aging, oncology, and inflammation. MelliCell's team has garnered recognition through awards and partnerships with leading biopharma companies, validating their technology. By advancing oral small molecules that shrink fat cells, MelliCell aims to enhance health outcomes and improve the quality of life for individuals affected by these diseases.

The Wake Forest Institute for Regenerative Medicine (WFIRM) is a leader in translating scientific discovery into clinical therapies. Physicians and scientists at WFIRM were the first in the world to engineer laboratory-grown organs that were successfully implanted into humans. Today, this interdisciplinary team is working to engineer more than 30 different replacement tissues and organs and to develop healing cell therapies-all with the goal to cure, rather than merely treat, disease.

Remedium Bio is a Boston-based gene therapy company dedicated to developing curative treatments for various debilitating conditions. The company employs a modular approach to research and development, utilizing established technologies in innovative ways to address well-understood disease mechanisms. By focusing on clinically validated molecules and targeted treatment strategies, Remedium Bio aims to create effective therapies for conditions within rheumatology, endocrinology, and neurology. Its pipeline includes promising gene therapy candidates designed to tackle a wide range of diseases, including immune and age-related disorders.

The University of Wisconsin-Madison is a prominent research institution and land-grant university located in Madison, Wisconsin. It provides a comprehensive range of liberal arts studies and professional programs, catering to diverse academic interests. The university's expansive campus offers approximately 600 undergraduate and graduate majors, alongside more than 9,000 courses across various disciplines, including fields such as accounting and zoology. Additionally, UW-Madison fosters a vibrant student life with numerous activities and organizations, enhancing the educational experience for its students.

Nexilico, Inc. is an early-stage biotechnology company based in Albany, California, specializing in precision medicine and microbiome research and development. Founded in 2017, the company focuses on creating advanced predictive computational platforms to enhance drug design and development processes. By pioneering next-generation in silico microbiome technologies, Nexilico aims to deepen the scientific understanding of microbiomes and their impact on health and disease. This knowledge is leveraged to create innovative microbiome-based solutions that improve therapeutic outcomes for various medical treatments.

North Carolina A&T State University is so many things to so many people, both in our state and around the country. North Carolina A&T State University is an HBCU. We are a top-flight research university, the largest historically black university (HBCU) in the country, the #1 producer of degrees awarded to African Americans in North Carolina and nationally recognized or our excellence in science, technology, mathematics and engineering (STEM) education. We are a diverse community, bound by intense pride and tradition, with fiercely loyal alumni who hold positions of importance and influence in companies and government agencies across the state, the country and the world. We are achievers, driven by a curious, limitless, fearless spirit that fuels discovery and innovation, resulting in 41 patents issued based on our research, as well as numerous spin-off and start-up companies. We are inclusive and welcoming, with students from many backgrounds and cultures, every part of our state, our nation and countries around the globe. We are passionate, driven by a desire to do more, be more and make more of a difference. Since we opened our doors in 1892, we have focused on giving every student the hands-on opportunities, core knowledge and global perspective that will lead them to make real and lasting change in their lives and the lives of others. At N.C. A&T, we have so much to be proud of, and you can learn more about those "Points of Pride" here. You can also use the links below to learn more about what makes N.C. A&T unique, from our leadership and history to our many rankings and recognitions.

Protabit specializes in protein engineering for various sectors, including industrial, agricultural, and healthcare applications. The company employs a unique platform technology that integrates computational modeling with high-throughput screening and directed evolution to enhance the diversity of protein sequences. This innovative approach allows Protabit to produce novel proteins tailored to specific needs. The development of their technology is supported by strategic partnerships with notable organizations, including Monsanto Company and the California Institute of Technology. Through its advanced methodologies, Protabit aims to advance the field of protein design and provide customized solutions for its clients.

Bespoke Biotherapeutics provides an effective natural immune response and overcomes the limitations of currently approved immunotherapies against cancer by inventing novel, customised living drugs called engineered B-cell therapeutics. They offer customised B-cell sourcing, isolation, activation, culture expansion, and non-viral genetic engineering methodologies uniquely suited to optimise commercial B-cell products for infusion.

Uniphage is a biotechnology company that specializes in developing innovative solutions to combat bacterial infections, with a focus on agriculture. It combines the power of bacteriophages, naturally occurring viruses that infect bacteria, with artificial intelligence to create precise and safe antimicrobial products. Uniphage's primary goal is to reduce the use of harmful fungicides, bactericides, and antibiotics in plant agriculture by providing more efficient and eco-friendly alternatives. By using AI algorithms to predict the effectiveness of bacteriophages against specific bacterial infections, Uniphage aims to accelerate the development of new pesticides, thereby minimizing risks to human health and the environment.

Simmbion specializes in innovative therapeutic solutions by utilizing symbionts to manufacture therapeutic agents directly within the human body, effectively transforming it into a living pharmacy. This technology aims to eliminate the challenges associated with traditional therapy manufacturing, such as the need for complex production processes, repeated injections, and temperature-sensitive storage. By providing a single injection that lasts up to 12 weeks, Simmbion's approach addresses supply chain disruptions and enhances affordability and accessibility of cell therapies for diverse patient populations. Their adaptable and universally immune compatible systems focus on delivering biological drugs directly in vivo, supporting a patient-centric and outcome-driven healthcare model while minimizing the risks of infections and immune rejection.

Ezrabio is a biotechnology company that specializes in RNA adenylation technology, facilitating ribosome profiling across diverse biological samples. By offering rapid cDNA library construction and streamlined services from sample preparation to deep sequencing, Ezrabio empowers researchers and medical professionals to uncover hidden coding potential, analyze translational responses, identify tumor-associated antigens, and inform mRNA therapeutics. Their innovative approach simplifies complex processes, making it easier for scientists to conduct critical research in genetics and molecular biology.

ViQi offers software-as-a-service solutions for scientific image analysis, catering to various sectors including life sciences, construction, and agriculture. The platform enables users to customize services for data storage and analysis through a straightforward subscription model. ViQi specializes in custom image processing and informatics, providing tools such as bio-image semantic queries, module development, and assistance with intranet deployment. This allows clients to efficiently view, investigate, share, and store complex data and images, facilitating swift results and discoveries in their respective fields.

Creative BioTherapeutics is a biotechnology company dedicated to developing innovative therapies for cancer and viral diseases. The company aims to transform cancer and viral disease research by targeting the fundamental issues of immune evasion and drug resistance. With a focus on recurrent and drug-resistant cancers, Creative BioTherapeutics is creating first-in-class biologics designed to address critical needs in treatment, particularly for patients with recurrent metastatic breast cancer. This approach not only seeks to enhance tumor regression but also holds the potential for cures in both adult and childhood cancers, thereby improving treatment options for patients facing these challenging conditions.

Cryptyx Bioscience is a biopharmaceutical company focused on discovering new therapeutic natural products from bacteria without the use of genetics or cloning. Their innovative platform aims to activate silent biosynthetic gene clusters within bacteria, allowing them to unlock the full potential of culturable microbes. By employing a bioactivity-first approach, Cryptyx seeks to rapidly identify new antibiotics and antiviral drugs, addressing critical needs in combating infectious diseases prioritized by health organizations. The company's technology is designed to provide a broad range of medical services and therapeutic applications, ultimately enhancing treatment options for patients.

PETL Fluidics operates a microfluidics platform designed for laboratory research. The company specializes in controlling, managing, and experimenting within microfluidic environments, facilitating a variety of applications such as chemical reactions, cell and organoid culture, advanced imaging, and mechanobiology. By providing custom-designed microfluidic solutions, PETL Fluidics aims to enhance the capabilities of laboratories engaged in cutting-edge scientific research.

Levisonics is a manufacturer of advanced blood coagulation instruments that specialize in non-contact analysis for blood coagulation and fluid quality control testing. Their products facilitate the assessment of bleeding and thrombosis risks through innovative fluid rheological measurement techniques. In addition to medical applications, Levisonics' technology can be employed in real-time monitoring of the quality of food, liquid, and gel products during production or processing, ensuring safety and compliance in various industries.

Cytocybernetics is a biotechnology company that specializes in cellular electrophysiology. The company has developed the Cybercyte, a user-friendly plug-and-play dynamic clamp system designed for ease of use in research settings. In addition to its innovative products, Cytocybernetics offers a comprehensive range of contract research organization (CRO) services, which include FDA-mandated drug safety screening, custom electrophysiology, custom modeling, and custom analysis. These services are aimed at assisting clients in the development and evaluation of various cellular products, ensuring that they meet regulatory requirements and scientific standards.

Amphix Bio is engaged in the development of advanced therapeutic materials aimed at regenerative medicine. The company specializes in creating nanofiber materials that replicate the structure and dynamic characteristics of human tissues. By integrating biological signals, these materials instruct cells to activate regenerative processes. Amphix Bio's innovations enable the development of therapies designed to repair a variety of tissues, including bone, cartilage, muscle, cardiovascular tissues, and the brain and spinal cord. The promising results observed in both preclinical and clinical trials highlight the potential of Amphix Bio's approach in transforming therapeutic applications in medicine.

Acrigen Biosciences focuses on enhancing the safety and efficacy of gene editing technologies, particularly those based on the CRISPR-Cas system. Founded in 2019 and headquartered in Berkeley, California, the company develops innovative solutions that aim to produce effective in vivo drug therapies to combat various diseases. Acrigen's proprietary technologies include Acro proteins that regulate the CRISPR-Cas gene editing process and an advanced bioinformatics discovery software platform that identifies suitable CRISPR systems for human therapeutic applications. Through these advancements, Acrigen Biosciences seeks to improve the precision, efficacy, and safety of genetic therapies, ultimately contributing to the potential prevention and cure of debilitating diseases.

Isolere Bio is a biotechnology company dedicated to simplifying the purification of biotherapeutics, particularly monoclonal antibodies and Adeno-Associated Viruses (AAV). Co-founded with the aim of enhancing global access to essential drugs, Isolere Bio develops innovative manufacturing technologies that utilize a straightforward Tangential Flow Filtration (TFF) setup. This approach facilitates a seamless transition from laboratory-scale processes to large-scale industrial production, thereby improving efficiency within the bioprocessing industry. As monoclonal antibodies continue to gain prominence as effective therapeutics and important research tools, Isolere Bio's work plays a crucial role in advancing the development of new diagnostics and treatments.

OmicsCraft offers customers access to a customised data analytics pipeline and a sample-to-solution service. They offer cloud-based platforms that allow them to build analytics pipelines for omic data preprocessing, mass spectrometric-based metabolite identification, differential analysis of metabolite profiles, and multi-omics integration.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

MBF Therapeutics, Inc. is a veterinary oncology company that specializes in developing and commercializing innovative therapies for cancer treatment in dogs and cats. The company's product portfolio features targeted immunotherapies and small molecule drugs designed to disrupt tumor cell metabolism while sparing healthy tissues. Key products include MBFT-101, a combination therapy for sarcomas and lymphoma that utilizes a proprietary polyamine transport inhibitor alongside a potent inhibitor of ornithine decarboxylase, and MBFT-102, an immunotherapy based on the tumor suppressor/cytokine mda-7/IL24, which has shown promise in human clinical trials for various advanced cancers. Additionally, MBF Therapeutics is advancing a gene-based vaccine platform aimed at improving treatments for both cancer and infectious diseases in animals, with the potential to transform veterinary medicine. The company is located in Ambler, Pennsylvania, and maintains a strategic partnership with the Lankenau Institute for Medical Research.

Aqueduct Fluidics, founded in 2019 and headquartered in Philadelphia, PA, specializes in developing automation solutions tailored for physical and life sciences research on laboratory benchtops. The company offers a software automation tool designed to streamline workflows and enhance the integration of hardware components. Its platform enables users to write automation scripts and provides an intuitive interface for controlling and visualizing hardware status. By simplifying system integration and addressing complex elements such as communication protocols, command timing, user interfaces, and data management, Aqueduct Fluidics equips developers with the necessary tools and resources to efficiently create, test, and deploy automation programs for benchtop-scale applications.

Vulcan Biologics is a biotechnology company based in Irvine, California, established in 2019. It specializes in the modulation of the microbiome through the use of bacteriophages, which are viruses that specifically infect bacteria without harming human cells. This innovative platform aims to achieve stable and persistent changes in the gut microbiome, facilitating the treatment of gluten-related disorders such as gluten sensitivity and celiac disease. By altering the composition of gut bacteria, Vulcan Biologics enables healthcare providers to offer targeted therapeutic solutions for individuals affected by these conditions.

Zymosense specializes in the development of an enzyme screening platform that utilizes innovative technology to identify and characterize enzymes with specific properties. The company offers automated aqueous two-phase extraction for the efficient sorting of chiral-pure single-walled carbon nanotubes, enhancing the scalability and cost-effectiveness of this process. Additionally, Zymosense has demonstrated the potential for automating the NIST-developed ATP system for the separation of these nanotubes. Their tools, including a plate reader and a handheld reader, leverage fluorescent nanoparticles suspended in target enzyme substrates to produce activity probes, ensuring accuracy while maintaining user-friendliness. This combination of technologies enables research scientists and biotechnology companies to rapidly evaluate, discover, and design new enzymes, thereby advancing various applications across multiple industries.

Synvivia, Inc. is a biotechnology company founded in 2016 and based in Berkeley, California. It specializes in developing synthetic biology products, particularly ON-OFF switches for genetically engineered organisms. These protein switches can be controlled by small molecules, allowing for precise manipulation of biological functions. By integrating these switches into organisms, Synvivia aims to create engineered life forms that can be effectively used in healthcare. The company also focuses on generating biosensors that enhance enzymatic activities, facilitating easier disease diagnosis and enabling healthcare providers to deliver appropriate treatments.

Cision Vision is a developer and supplier of advanced imaging medical products focused on enhancing the examination of lymph nodes. Their innovative technology allows pathologists to visualize, scan, and record lymph nodes in real time with high contrast, without the need for injections or radiation. This capability supports the modernization of pathology practices, ensuring consistency and high-quality care in medical diagnostics. By providing these biotechnology tools, Cision Vision aims to improve the efficiency and accuracy of lymph node assessments in clinical settings.

Spekciton Biosciences specializes in biophotonic measurement systems and services aimed at enhancing agricultural performance and sustainability. The company develops innovative technologies that enable the rapid and precise detection of plant stress and viability, providing farmers with essential insights for improving crop management. Additionally, Spekciton offers biosensors designed to quickly identify soil and water contamination, supporting environmental health and agricultural productivity. Through its advanced measurement solutions, the company contributes to a better understanding of bioprocesses, ultimately aiding in the cultivation of resilient and sustainable crops.

Aracari Biosciences specializes in developing advanced 3D Vascularized Micro-Organ platforms aimed at improving the drug discovery process. These platforms enhance the biological authenticity of pre-clinical testing by allowing for real-time imaging of vessel morphology, which facilitates the investigation of lead compound efficacy against tumors in a three-dimensional environment. The technology is designed to adapt to various physiological conditions and can be perfused with fluorophore-tagged dextrans of different molecular weights. This capability assists pharmaceutical companies in making informed decisions and accelerates the development of new drugs.

Envivo Bio develops a non-invasive device that collects microbiome samples from all regions of the human gastrointestinal tract. The company is based in San Carlos, California.

Soil Culture Solutions, LLC, founded in 2014 and headquartered in Tampa, Florida, specializes in innovative genetic alteration technology. The company focuses on developing citrus trees that utilize CRISPR editing techniques to enhance resistance to severe diseases affecting the citrus industry. Soil Culture Solutions holds exclusive licenses to patents from community universities, enabling it to employ precision breeding methods to combat these critical infections in citrus crops.

Felix Biotechnology, founded in 2019 and based in San Francisco, California, is focused on developing biotherapeutics aimed at addressing microbial challenges in human health, particularly antibiotic-resistant strains of bacteria and fungi. The company aims to accelerate the deployment of innovative treatments for infectious diseases, enabling healthcare professionals to manage these urgent health threats effectively. Through its targeted approach, Felix Biotechnology seeks to provide precise and effective solutions to combat the growing issue of antibiotic resistance.

xMD Diagnostics, based in Annapolis, Maryland, specializes in biotechnology within the healthcare sector. The company develops molecular diagnostics tools that use high-throughput microdissection technology to improve cancer diagnosis and management. These tools are designed to isolate, procure, and enrich cells of interest from biopsy and other specimen samples. This process facilitates various downstream analyses, including PCR, genomic or proteomic testing, and next-generation sequencing. By enhancing the capabilities of clinical and research laboratories, xMD Diagnostics supports pathologists, oncologists, and other healthcare professionals in diagnosing, monitoring, and treating patients with cancer and serious genetic diseases.

Tethys Research focuses on discovering high-value enzymes and chemical entities by applying its expertise across various disciplines to address challenges unsuitable for high-throughput screening methods. The company operates as a discovery entity, creating innovative technologies and collaborating with organizations that manufacture and market chemical products and processes. Through its contract and partnership initiatives, Tethys Research aims to enhance the capabilities of businesses in the chemical industry by providing tailored solutions that meet specific needs.

TheraCea Pharma is a biotechnology company based in Tucson that focuses on developing precision medicine for individuals with neurological disorders. As a spin-off from the University of Arizona, the company has developed and licensed advanced radiochemistry technology that enables efficient and rapid fluorine-18 radiolabeling of biomolecules. This innovative approach supports both clinical and research applications, particularly in the context of neurological conditions. TheraCea Pharma's treatments aim to counteract dyskinesia, a side effect commonly associated with L-dopa, the standard treatment for Parkinson's disease. By providing new diagnostic agents, the company enhances medical professionals' capabilities in detecting not only neurological disorders but also cancer, thereby contributing to improved healthcare outcomes.

Frontier Bio Corporation, based in Oakland, California, develops and manufactures advanced bioprinting technologies to create lab-grown human tissues. Established in 2018, the company offers the FLUX-1, a 3D bioprinter that integrates conventional bioprinting methods with electro-hydrodynamic printing capabilities. This technology enables the production of complex tissues, such as skin, cartilage, and bone, while also facilitating drug toxicity testing, tissue implants, drug screening, and disease modeling. Frontier Bio aims to replace animal studies with ethically developed human tissues, ultimately working towards eliminating the organ transplant waitlist and improving patient outcomes. The company focuses on achieving complete cell survivability during the printing process, ensuring the viability of the printed tissues for various medical applications.

Nano PharmaSolutions specializes in enhancing the bioavailability of insoluble drugs through its proprietary nanoformulation technology. The company has developed an innovative phase-transition technology platform that significantly improves the solubility of BCS 2 and BCS 4 active pharmaceutical ingredients (APIs) without the need for excipients, which are typically used in traditional processes like spray-dry dispersion and emulsification. By vaporizing the API and depositing it onto a carrier molecule, Nano PharmaSolutions enables the production of nanoparticles that can be processed into various dosage forms. Additionally, the company focuses on delivering neurodegenerative therapeutics directly to the brain via an intranasal route, facilitating a rapid onset of action and enhancing safety profiles. Their pipeline includes treatments for conditions such as Parkinson's disease, peripheral neuropathy, and substance abuse disorders, positioning Nano PharmaSolutions as a key player in the field of nanomedicine.

Ancilia Biosciences focuses on developing engineered bacterial therapies aimed at treating diseases associated with the microbiome. The company specializes in creating virus-resistant live bacterial products that modulate the human microbiome, specifically targeting the viral components within the gut microbiome. By concentrating on healthy gut bacteria and their predatory phages, Ancilia engineers resistant bacterial strains to combat diseases. Its innovative approach includes the development of a new class of live biotherapeutics that allows medical professionals to target specific phages or viruses that induce lysis, with applications in immunology and oncology.

Hermes Life Sciences develops solutions to improve the accuracy and accessibility of blood testing at the point of care. The company was founded by Sasank Vemulapati.

InSoma Bio integrates biology and materials science to solve problems in tissue engineering and regenerative medicine. It offers genetically engineer protein-based materials that can mimic the naturally found elastin found in extracellular tissues. The company also offers reconstructive plastic surgeries and injectable materials.

Stellate DNA, founded in 2020 and based in Cambridge, Massachusetts, specializes in proprietary DNA donor technology aimed at synthesizing and producing single-strand DNA donors. The company employs a clonal synthesis platform rather than traditional chemical methods, enabling the production of customizable gene knock-in payloads. This approach ensures well-controlled production at microgram to milligram scales, assisting medical professionals in achieving minimal mutation rates and maintaining sequence uniformity. Through its innovative technology, Stellate DNA addresses the demands of the biotechnology sector while supporting advancements in genetic research and therapeutic applications.

Partillion Bioscience is an early-stage life science company focused on developing a functional single-cell analysis platform. This innovative platform utilizes a novel nano vial technology to rapidly compartmentalize and analyze millions of single cells, specifically targeting secreted proteins. By enabling detailed examination of biological functions, Partillion aims to democratize advanced single-cell assays for biotech laboratories and clients. This capability supports the development of more effective therapies for various conditions, including cancer, autoimmune diseases, and infectious diseases.

Gate Scientific makes products that enable great research and improve healthcare decisions by bringing to market intuitive solutions that simplify complex problems. By bringing to market intuitive solutions that simplify complex problems, they allow for the latest technologies to benefit more people.

Kingdom Supercultures specializes in the development and production of microbial cultures that assist food manufacturers in creating innovative food products. Founded in 2019 and based in Brooklyn, New York, the company offers Koji, a traditional Japanese ingredient used in various fermented foods and beverages. Their technology utilizes an extensive biobank of Generally Recognized As Safe (GRAS) microbial strains and employs automated systems to characterize and assemble these strains into new combinations. This enables the production of plant-based foods that replicate dairy flavors, low-alcohol beverages with rich taste, and effective natural preservatives. Kingdom Supercultures collaborates with clients across multiple sectors, including food, beverage, personal care, and beauty, focusing on enhancing the health and sustainability of food offerings.

NellOne Therapeutics, Inc. is a regenerative medicine company based in Oak Ridge, Tennessee, focused on developing and commercializing protein therapeutics aimed at restoring cardiac muscle mass and function in patients recovering from myocardial infarctions and congestive heart failure. The company was established as a spin-off from the U.S. Department of Energy's Oak Ridge National Laboratory, where research on the Nell1 gene's pathway was conducted, revealing its role in the formation of critical mammalian tissues and organs. Founded by Battelle Ventures, NellOne is dedicated to translating this scientific discovery into effective clinical applications for heart recovery.

Precision Theranostics is a biotechnology company based in Baltimore, Maryland, founded in 2019. The company focuses on developing prognosis-based intervention strategies aimed at the early detection and treatment of fatal diseases. Its innovative platform is designed to estimate disease progression, particularly for respiratory diseases and age-related disorders. By creating novel diagnostics, therapeutics, and prognosis-based therapies, Precision Theranostics enables healthcare providers to deliver timely diagnoses and interventions, ultimately improving survival rates and preventing the progression of chronic and fatal conditions.

Allegro 3D specializes in Digital Light Processing (DLP) printing technology, focusing on bioprinting applications. The company develops a platform that facilitates the high-precision and high-throughput manufacturing of advanced biomedical devices and human tissues. This technology is aimed at enhancing the creation of tissue models for drug screening, therapeutics, and regenerative medicine. By enabling the production of intricate cell matrices and precision tissues, Allegro 3D supports advancements in biofabrication systems, contributing to significant innovations in healthcare, particularly in drug discovery and biomedical research.

CellDrop Biosciences, established in 2017 and based in Laramie, Wyoming, specializes in hydrogel-based technology for point-of-care diagnostics and targeted biomaterial delivery. The company focuses on developing hydrogel platforms that enable precise control over chemical and biological systems. Its innovations aim to facilitate the healing of equine musculoskeletal injuries efficiently, while also minimizing the risk of re-injury. By providing effective diagnostic and treatment solutions, CellDrop Biosciences addresses critical needs within the veterinary medical community.

FluidForm Bio is a biotechnology company focused on creating living human tissue to enhance disease treatment. Utilizing its patented FRESH technology, the company specializes in 3D bioprinting, which enables the production of high-quality tissue that mimics real human tissue by integrating cells and proteins without additional materials. This innovative platform allows for the design and fabrication of complex tissue structures with embedded vasculature and multiple materials within a single print. Through collaborations with leading life science companies, FluidForm Bio's technology has been validated for various applications, paving the way for novel therapeutic programs in the healthcare sector. Founded in 2018 and headquartered in Waltham, Massachusetts, FluidForm Bio aims to provide better treatment options for patients through its transformational approach to tissue engineering.

Kepley BioSystems is focused on developing innovative technologies aimed at addressing significant challenges in both marine and healthcare sectors. The company offers ocean restorative technology designed to combat the depletion of wild fish populations, promoting sustainable practices in marine ecosystems. Additionally, Kepley BioSystems is advancing life science solutions that provide accurate methods for testing dangerous endotoxins. Their platform focuses on healthcare innovations, specifically in the detection of blood-borne pathogens, enabling physicians to deliver rapid and sensitive diagnostics for bloodstream infections. Through these efforts, Kepley BioSystems aims to contribute to environmental sustainability and improve health outcomes.

Sears Scientific specializes in developing innovative scientific equipment designed to enhance the usability and accessibility of tools used in research. By streamlining processes in fields such as microscopy and vacuum sciences, the company enables researchers to concentrate more on scientific discovery rather than the complexities of their instrumentation. Through its focus on improving the ease-of-use of scientific technologies, Sears Scientific aims to facilitate advancements in research and support the scientific community.

Amberstone Biosciences specializes in the discovery of novel immunotherapies aimed at addressing unmet medical needs through advanced technologies and strategic collaborations. The company focuses on challenging therapeutic targets that require unique mechanisms of action, which traditional methods struggle to tackle. Amberstone employs a microfluidics-powered drug discovery platform, known as AmberFlow, to analyze single-cell functions within a customizable microenvironment. This innovative approach allows for a more precise understanding of immune responses, enabling the development of transformative therapeutic antibodies. The team's expertise in immuno-oncology and single-cell assay biology further enhances their capacity to create effective treatments, ultimately improving patient outcomes.

Impact Proteomics, LLC specializes in protein sample preparation, offering a range of kits and reagents designed to produce contaminant-free samples. Founded in 2017 and based in Pittsburgh, Pennsylvania, the company provides various products, including Universal Protein Extraction and Clean Kits for peptides, whole proteins, and immunoprecipitation, as well as Promtag Reversible Protein Tagging Agents and related accessories. By supplying tools for efficient protein handling, Impact Proteomics aims to enhance drug and biomarker discovery processes, allowing researchers to accelerate the development of therapeutics and diagnostics. The company's offerings are available for purchase online, reflecting its commitment to supporting the scientific community in advancing medical research.

NeyroblastGX is a biotechnology company established in 2020 and based in Murrieta, California, focused on developing theranostic products aimed at treating neurodegenerative and infectious diseases. The company’s product offerings include a blood-based biomarker diagnostic for Alzheimer's, genetically engineered dendritic cells designed to eliminate custom-made human organoids for drug screening, cellular toxicity assessment, and disease pathology. Additionally, NeyroblastGX develops an oral supplement intended to enhance protective immunity, providing patients with a comprehensive portfolio of diagnostics, drugs, and therapies to combat life-threatening conditions.

DPX Technologies, founded in 2007 and based in Columbia, South Carolina, specializes in patented pipette tip technology aimed at enhancing the quality of products used in complex chemical and biological analyses. The company's innovative technology is designed for automated liquid handling systems, offering customizable solutions that simplify and automate intricate sample preparation processes. This enables scientists to efficiently implement automated solutions that can be tailored to various laboratory workflows and methods, thereby improving overall analytical performance in research and development settings.

Nabla Bio operates an autoreverse platform that facilitates the rapid discovery of novel protein variants with unique properties. By leveraging insights gained from billions of natural proteins, the company engineers these enhanced proteins for both medical and industrial applications. Through extensive experimentation, Nabla Bio develops new medicines and improves nutritional products, allowing clients to conduct complex measurements of protein function and implement innovative solutions in various fields.

New Horizon Biotech specializes in biotechnology and biopharmaceutical products, focusing on optimizing supply chains and ensuring consistent quality globally at a reduced cost. The company is finalizing tests of its patented Single Use Horizontal Fermentor system (SUHF™), which is designed for single-use microbial fermentation. This innovative system is set to enhance production efficiencies and operational cost savings, offering significant advantages over traditional fermentor designs. By improving the microbial fermentation process, New Horizon Biotech aims to support the production of high-value biopharmaceuticals, including antibiotics, vaccines, and therapeutic proteins, thereby strengthening the global competitive edge of its clients.

Cobio Diagnostics is a biotechnology company based in Golden, Colorado, founded in 2016. The company specializes in developing diagnostics aimed at rapid bacterial identification and phenotypic antibiotic resistance testing. Utilizing a phage-based immunoassay, Cobio Diagnostics' technology can identify specific bacterial species and determine the most effective antibiotic treatment in under five hours. This innovative approach provides a faster and more targeted alternative to traditional diagnostic methods, allowing healthcare providers to make quicker and more informed decisions regarding antibiotic treatment for patients with bacterial infections.

CytoRecovery, Inc. specializes in developing microfluidic technology aimed at recovering and testing subpopulations of cancer cells from tumor biopsies and other biological samples. Founded in 2017 and based in Blacksburg, Virginia, the company provides tools that allow cell biologists and life science researchers to efficiently select and recover rare, homogeneous, and viable cell subpopulations from various sources, including tissue and blood. The technology facilitates precise cell biology analytics by offering individual trapping and release of these rare cells for downstream analysis, thus enhancing research capabilities in the study of cancer and other diseases.

Florica Therapeutics, founded in 2019 and based in Livermore, California, focuses on developing exosome-based therapeutics aimed at extending lifespan and preventing age-related diseases. The company specializes in delivering drugs to the brain, offering innovative treatment alternatives for serious conditions such as leukemia and Tay-Sachs disease. By advancing these therapeutics, Florica Therapeutics seeks to improve patient outcomes and enhance the quality of life for individuals affected by terminal illnesses.

Nano RED specializes in precision delivery technologies aimed at advancing RNA and immunotherapeutics for cancer treatment. The company develops innovative immunotherapy solutions that utilize liposomes, which are injected into the bloodstream. This approach allows for the direct release of cancer therapies into tumors and their surrounding environments, while also addressing the associated toxicity within the body. Through its cutting-edge technology, Nano RED seeks to enhance the effectiveness of cancer treatments and improve patient outcomes.

CasTag Biosciences is focused on advancing cell biology and regenerative medicine through innovative tools that enhance the analysis of endogenous proteins. By developing adeno-associated virus kits, the company aims to expedite scientific discovery and empower researchers to investigate novel genes across various experimental models. Utilizing a unique two-vector, clustered regularly interspaced short palindromic repeats-based gene editing technique known as homology-independent universal genome engineering, CasTag's products enable the modification of entire panels of proteins within cells and tissues, thereby facilitating a deeper understanding of biological processes.

AthemBio is a biotechnology company focused on addressing significant challenges in biologics manufacturing through innovative technologies. The company specializes in developing advanced medical devices and bioprocessing systems designed to isolate and purify therapeutic antibodies. These solutions aim to enhance the treatment of COVID-19 and other infectious diseases, ultimately contributing to the fight against pandemics and emerging pathogens. AthemBio's commitment to creating effective bioprocessing solutions positions it as a key player in the healthcare sector.

Ramona develops advanced microscopy tools designed to enhance cellular-level research by capturing detailed images over vast areas. The company's innovative microscope employs custom control electronics to efficiently process large volumes of image data from multiple micro-cameras, allowing researchers to capture and analyze extensive gigapixel datasets. This capability not only provides a wider field of view but also enables synchronous data capture, allowing for real-time observation of cellular processes. By offering a new perspective on cellular dynamics, Ramona's technology empowers researchers to make more informed decisions quickly and effectively.

GRI Bio, Inc. is a clinical-stage biotechnology company based in La Jolla, California, focused on developing innovative therapies for liver disease and autoimmune disorders. The company specializes in harnessing Natural Killer T (NKT) cell-based therapies to address dysregulated immune responses associated with inflammatory and fibrotic diseases. One of its primary product candidates, GRI-0621, is an oral small molecule that inhibits type 1 NKT cells, aiming to restore immune system balance in patients with liver conditions. Additionally, GRI Bio is advancing GRI-0803, an oral agonist targeting type 2 NKT cells. Established in 2009, GRI Bio is committed to discovering and commercializing effective treatments for serious health challenges linked to immune system dysfunction.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. Founded in 2013, the company is advancing several product candidates, including tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic aimed at treating MDR gram-negative infections in adults. Additionally, Spero is developing SPR206, an intravenous agent for MDR gram-negative infections in hospital settings, and SPR720, an oral antibiotic targeting pulmonary non-tuberculous mycobacterial disease. The company collaborates with various partners, including Meiji Seika Pharma to support tebipenem HBr's development and the Bill & Melinda Gates Medical Research Institute for SPR720. Spero Therapeutics employs a focused approach to drug development, emphasizing novel mechanisms to address the urgent need for effective therapeutics against serious bacterial infections.

Silvec Biologics specializes in developing RNA therapies aimed at treating and preventing diseases in trees, vines, and bushes. By employing RNA-based molecules, the company offers innovative solutions that eliminate the need for genetic modification. Its therapies work by introducing virus-like RNA into the plant's vascular system, effectively targeting and destroying viral and fungal pathogens. This approach not only safeguards the health of these plants but also supports food growers in maintaining abundant and diverse food supplies, thereby contributing to the preservation of natural resources and ensuring sustainability for future generations.

iReprogram is a cell regeneration laboratory based in Ann Arbor, Michigan, established in 2017. The company focuses on advancing personalized medicine through innovative cell reprogramming technology. By utilizing a high-fidelity computational tool, iReprogram generates transcription factor recipes aimed at facilitating cellular trans-differentiation. This approach enhances treatment options for cancer patients, contributing to improved therapeutic outcomes. Through its research and development efforts, iReprogram seeks to accelerate the delivery of next-generation medical solutions tailored to individual patient needs.

CO2 Sync, founded in 2019 and based in Cody, Wyoming, specializes in the development of genomically optimized plants aimed at achieving specific desired traits. The company operates in stealth mode, focusing on innovative agricultural solutions to enhance plant performance and adaptability.

Progenitor MDX is engaged in developing cellular immunotherapy technologies that facilitate the creation of induced pluripotent stem cells for use in immune-oncology and engineered cell therapies. The company combines all Yamanaka factors into a single vector, enabling simple and reliable cellular reprogramming. This innovation supports the efficient production of allogeneic off-the-shelf CAR constructs derived from various cell sources. In addition to its focus on cellular immunotherapy, Progenitor MDX offers a comprehensive and customizable solution for managing COVID-19 infections, which includes providing testing results and actionable plans for infection management to support community health.

GMJ Technologies, founded in 2018 and based in Seattle, Washington, specializes in developing microanalytical technologies for biopharmaceutical and biomedical applications. The company focuses on creating robust analytical tools and integrated technologies that enhance proteomics and protein-based biologics workflows. By streamlining research, development, and manufacturing processes, GMJ Technologies aims to advance the capabilities of analytical methodologies in the life sciences sector.

Akanocure Pharmaceuticals is a biotechnology company focused on developing innovative anti-cancer chemotherapeutic drugs aimed at treating various forms of cancer. The company is dedicated to finding therapeutic approaches that effectively block the metastatic processes responsible for 90% of cancer-related deaths. By harnessing the expertise of its team throughout the drug discovery and development phases, Akanocure aims to create novel small molecules derived from natural resources. These bio-targeted therapeutics are designed not only to combat cancer but also to alleviate the side effects associated with chemotherapy and other cancer treatments, ultimately improving the quality of life for patients.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

Vaxess Technologies, Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2011. The company focuses on developing and commercializing innovative silk biomaterial technologies. Its key product, the MIMIX microneedle platform, facilitates the transdermal delivery of vaccines and therapeutics. This sustained release patch technology allows for a controlled release of vaccines, mimicking the natural infection process to enhance immune response and effectiveness. Vaxess's patch is engineered for stability, eliminating the need for refrigeration, which enables shipping and application in low-resource settings. In addition to its vaccine delivery systems, Vaxess is also engaged in creating novel therapies aimed at oncology care and infectious diseases, ultimately striving to improve patient outcomes with reduced treatment burdens.

Creative BioTherapeutics is a biotechnology company dedicated to developing innovative therapies for cancer and viral diseases. The company aims to transform cancer and viral disease research by targeting the fundamental issues of immune evasion and drug resistance. With a focus on recurrent and drug-resistant cancers, Creative BioTherapeutics is creating first-in-class biologics designed to address critical needs in treatment, particularly for patients with recurrent metastatic breast cancer. This approach not only seeks to enhance tumor regression but also holds the potential for cures in both adult and childhood cancers, thereby improving treatment options for patients facing these challenging conditions.

Optimeos Life Sciences is a biotechnology company focused on developing advanced drug delivery systems that utilize biologics, peptides, and RNA for disease treatment. The company has created encapsulation technology that enhances the efficacy of these therapeutic agents by protecting them and ensuring their precise delivery to targeted areas within the body. This innovation addresses existing challenges in the field of biologics and peptide therapeutics, facilitating sustained release of these treatments through the use of nano-composite microparticles. By improving the delivery mechanism, Optimeos Life Sciences aims to enhance patient outcomes in the management of various diseases.

Inanovate Inc. specializes in developing protein screening and analysis products for the life sciences sector. The company offers the Bio-ID platform, a protein screening biochip that provides real-time, sensitive kinetic data on multiple protein interactions. This technology is applicable in various areas, including protein research, drug development, quality control, biomarker profiling, validation, and clinical diagnostics. Inanovate also provides biomarker alliance programs, i-Slide nano-particle surface technology for protein immobilization, and a range of protein micro-array services, such as assay development and support. The company serves researchers, clinical centers, and biotech and pharmaceutical firms. Founded in 2006 and headquartered in Sioux Falls, South Dakota, Inanovate has an additional office in Raleigh, North Carolina, and operates in the United States and the United Kingdom.

Think Bioscience is focused on advancing synthetic biology to enhance the design and assembly of improved medicines. The company utilizes a unique technology that encodes complex molecular objectives into microbial hosts, facilitating the identification, construction, and evolution of small molecules. This innovative approach allows medical researchers to leverage microbes in the drug discovery process, potentially leading to more effective therapeutic solutions. Through its efforts, Think Bioscience aims to transform how medicines are developed and contribute to the future of healthcare.

Cornerstone Genomics, established in 2017 and based in Frederick, Maryland, specializes in providing expert guidance on the application of genomic tools in human disease research, biomedicine, veterinary sciences, and wildlife conservation. The company operates a biotechnology platform that houses proprietary DNA and protein sequence databases, along with applications designed to meticulously filter, annotate, and predict the functional impact of genetic variants. This precision enables researchers to accurately identify disease-causing genetic changes, facilitating the development of targeted therapies and gene therapies for inherited diseases.

Seven Biosciences provides drug discovery platforms for G-protein coupled receptors. The company, based in Davis, California, was founded by Grace Mizuno and Lin Tian.

Ionica Sciences, Inc. is focused on developing a spectroscopy-based diagnostic platform that utilizes surface enhanced Raman scattering (SERS) technology. Founded in 2013 and headquartered in Ithaca, New York, the company aims to address urgent needs in clinical diagnostics by enabling rapid and accurate identification of vector-borne, sexually transmitted, and neurological diseases. Ionica Sciences is particularly dedicated to creating in-vitro diagnostic assays for Lyme disease and other infectious conditions, allowing medical professionals to detect biologically relevant targets such as pathogens and hormones. By improving diagnostic accuracy, the company seeks to reduce patient suffering, minimize unnecessary antibiotic use, and lower healthcare costs associated with misdiagnoses.

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation, and immunological disorders. Plexision's first patented product, the PleximmuneTM assay, predicts the risk of transplant rejection. The test is based on patent-pending technology to measure antigen-specific white blood cells. Testing services for transplant recipients and drug developers are provided at Plexision’s CLIA-certified, central laboratory in Pittsburgh. Plexision currently offers cell-based testing for personalized assessment of rejection risk after solid organ transplantation The Pleximmune blood test is the first such test offered for children with liver or intestine transplantation.

Ascribe Bioscience is a company focused on developing environmentally friendly crop protection products that help farmers combat pathogens affecting their crops. Founded in 2017 and based in Ithaca, New York, the company is currently working on a seed treatment product designed to enhance crops' natural defenses against diseases such as Rhizoctonia. By researching the interactions between microbes and plants at the molecular level, Ascribe Bioscience identifies the signaling molecules that activate plants' innate immunity. This innovative approach aims to improve both the quality and productivity of agricultural yields while minimizing negative environmental impacts.

ActivSignal, established in 2016 and based in Natick, Massachusetts, specializes in biotechnology. The company focuses on developing innovative protein profiling technologies, primarily serving the proteomics research sector. Their tools enable scientists to analyze multiple signaling pathways simultaneously, providing insights into cellular pathway activation or inhibition profiles.

Jupiter Therapeutics is a biotechnology company specializing in the development of cell-membrane-based therapeutics. The company employs a synthetic biology approach to rapidly design and synthesize a diverse pipeline of therapeutic assets targeting cancer, autoimmune diseases, drug delivery, and gene therapy. By utilizing advanced cell engineering techniques, Jupiter Therapeutics creates customized vesicles that enhance immuno-oncology applications and gene therapy strategies. This innovative approach allows medical researchers to leverage insights gained from cell-membrane studies to improve treatments involving CAR T-cells and bi-specific antibodies.

GRO Biosciences is focused on developing advanced protein therapeutics by utilizing innovative technologies in computational protein design and synthetic biology. The company has created several genomically recoded strains of bacteria that enable the incorporation of non-standard amino acids into proteins. This approach enhances the potency, stability, and targeted delivery of these therapeutics. GRO Biosciences aims to apply its technology to improve treatments for a range of conditions, including diabetes, growth disorders, and autoimmunity, thereby addressing significant unmet medical needs.

Acrigen Biosciences focuses on enhancing the safety and efficacy of gene editing technologies, particularly those based on the CRISPR-Cas system. Founded in 2019 and headquartered in Berkeley, California, the company develops innovative solutions that aim to produce effective in vivo drug therapies to combat various diseases. Acrigen's proprietary technologies include Acro proteins that regulate the CRISPR-Cas gene editing process and an advanced bioinformatics discovery software platform that identifies suitable CRISPR systems for human therapeutic applications. Through these advancements, Acrigen Biosciences seeks to improve the precision, efficacy, and safety of genetic therapies, ultimately contributing to the potential prevention and cure of debilitating diseases.

Spira focuses on developing algae-based ingredients designed to replace petroleum and animal-derived compounds, promoting sustainability in various industries. The company specializes in creating food-safe dyes and other industrial ingredients, which are utilized across sectors such as beverages, cosmetics, textiles, and confectionery. By collaborating with a global network of farming partners, Spira aims to manufacture raw materials that contribute to carbon capture and wastewater management. Their efforts not only support the transition to more sustainable materials but also assist in improving the livelihoods of farmers in developing countries. Through its innovative products and services, Spira is committed to enhancing both human and planetary health.

StabiLux Biosciences specializes in the production of high-brightness fluorophores aimed at enhancing the performance of reagents used in flow cytometers. The company offers a drop-in platform technology that allows researchers to detect previously undetectable entities while maximizing the capabilities of existing equipment without the need for additional components or software. StabiLux's innovative fluorophores increase brightness across the visible spectrum, significantly improving detection of targeted or cancer cells with minimal noise distortion. This approach enables more effective analysis in various research applications.

Tempo Therapeutics is a life science company focused on advancing regenerative medicine through innovative materials that are immune stealth and minimally invasive. The company harnesses immunomodulation and material science to create cell-free synthetic hydrogels designed to unlock the body's natural regenerative capabilities. By employing geometric technology, these materials can effectively control inflammation and promote accelerated healing rates. Tempo Therapeutics aims to transform medical technology by developing synthetic tissue hybrids applicable to various bodily tissues, including skin, bone, heart, and brain, while minimizing the risk of immune rejection commonly associated with traditional approaches.

Prime Labs is a company focused on enhancing drug discovery through its cloud-based software platform, which specializes in mass spectrometry data processing, analysis, reporting, and visualization. The software is designed to support a variety of instruments and workflows, enabling scientists to conduct experiments with greater accuracy and efficiency. By streamlining the data processing experience, Prime Labs offers a user-friendly solution that minimizes the complexity typically associated with such tasks, allowing researchers to focus on their work with minimal training or installation requirements. This innovative approach facilitates a broader range of experiments in a shorter time frame, ultimately contributing to advancements in medical research and drug development.

Nanocrine specializes in developing advanced cell biology platforms aimed at enhancing live cell microscopy and experimentation. The company offers a range of products, including self-assembled monolayer surface chemistry biochips and protein coupling kits, which allow researchers to utilize specific proteins or peptides with precision. Their innovative solutions facilitate the study of various cell types, such as astrocytes and cardiomyocytes, and support applications in serum-free cell culture and virus detection. By providing tools that enable the monitoring of molecular communications between cells, Nanocrine aims to contribute to significant advancements in understanding human disease progression, injury recovery, and overall wellness.

New Equilibrium Biosciences is focused on developing therapeutic drugs aimed at treating cancer and neurodegenerative diseases. The company employs a unique approach that integrates artificial intelligence with quantum chemistry to enhance biophysical experiments. This innovative platform specializes in the research and development of therapeutics that target intrinsically disordered proteins (IDPs), which are often implicated in various neurodegenerative disorders. By utilizing IDP-specific compound libraries, New Equilibrium Biosciences seeks to identify and exploit transient binding pockets on these proteins, facilitating the discovery of lead drug candidates. This approach aims to improve medical procedures and ultimately contribute to advancements in healthcare.

A-Alpha Bio, Inc. is a biotechnology company based in Seattle, Washington, established in 2017. The company specializes in synthetic biology, offering a platform known as AlphaSeq, which assists pharmaceutical companies in the development of drugs that interact with multiple targets. A-Alpha Bio provides cell-based tools for high-throughput and quantitative measurements of protein interactions, facilitating target discovery, library screening, and preclinical drug characterization. Its proprietary technology enables the mapping of protein-protein interactions at a large scale, allowing for the identification and quantification of interactions among thousands of protein pairs simultaneously. By delivering detailed maps of these interactions, A-Alpha Bio helps researchers identify potential drug targets and understand disease mechanisms, thereby streamlining the therapeutic discovery process and improving the efficiency of drug development. The company comprises a team of experts in synthetic biology, structural biology, and next-generation sequencing, focused on overcoming challenges in the drug development pipeline.